ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen. Issue 42 (8th October 2018)

• Record Type: Journal Article
• Authors: Carrell, Rebecca K.; Stanton, Rebecca A.; Ethier, Stephen P.; LaRue, Amanda C.; Soloff, Adam C.
• Is Part Of: Vaccine. Volume 36:Issue 42(2018)
• Page Start: 6262
• Page End: 6269
• Publication Date: 2018-10-08
• Subjects: Cancer vaccine -- Adenoviral vectors -- Inducible T cell costimulatory (ICOS) ligand -- T helper 17 cells (Th17) -- MUC1; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.09.010
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Cellular immunity established via immunotherapy holds the potential to eliminate solid tumors. Yet, cancer vaccines have failed to induce tumor-reactive T cells of sufficient quality to control disease. The inducible T cell costimulator (ICOS) pathway has been implicated in both the selective induction of immunity over tolerance as well as licensing of IL-17-polarized cellular immunity. Herein, we evaluated the ability of ICOS ligand (ICOSL) to augment the immunogenicity of adenoviral-based vaccination targeting the unglycosylated MUC1 peptide antigen. Vaccination disrupted immunotolerance in a transgenic mouse model recognizing human MUC1 as a self-antigen, inducing robust MUC1-specific immunity. Augmenting vaccination with ICOSL induced a bipolar Th17/Th1 effector profile, marked by increased MUC1-specific IL-17A production and RORγt expression in CD4 + but not CD8 + T cells which predominantly expressed IFNγ/IL-2 and T-bet. The polarization and maintenance of Th17 cells established following ICOSL augmented vaccination was highly durable, with elevated IL-17A and RORγt levels detected in CD4 + T cells up to 10 months after initial immunization. Furthermore, provision of ICOSL significantly enhanced MUC1-specific IgG antibody in response to immunization. ICOSL signaling dramatically influenced CD4 + T cell phenotype, altering gene expression of transcription factors and regulators of effector function following immunization. Interestingly, ICOSL augmentation failed to alter the transcriptional profile of CD8 + T cells following immunization, affecting the magnitude, but not distribution, of gene expression. Collectively, ICOSL supports the induction of durable, antigen-specific Th17/Th1-mediated immunity in vivo, establishing a vaccination platform to enhance CD4 + T cell-mediated antitumor immunity and providing a crucial component of an effective cancer vaccine.